Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearbridge HealthFRA:5C6 EV-to-EBITDA is -0.87 as of Sep. 12, 2026. The stock has 4 warning signs investors should review. Among 123 Medical Diagnostics & Research companies, Clearbridge Health ranks worse than 813007.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clearbridge Health's enterprise value is €6.52 Mil.
Clearbridge Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-7.48 Mil. Therefore, Clearbridge Health's EV-to-EBITDA for today is -0.87.
The historical rank and industry rank for Clearbridge Health's EV-to-EBITDA or its related term are showing as below:
FRA:5C6'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.75 Med: -3.38 Max: 11.67
Current: -0.85
During the past 12 years, the highest EV-to-EBITDA of Clearbridge Health was 11.67. The lowest was -19.75. And the median was -3.38.
FRA:5C6's EV-to-EBITDA is ranked worse than 100% of 123
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.06
vs FRA:5C6: -0.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Clearbridge Health (FRA:5C6) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clearbridge Health's PE Ratio (TTM) for today is calculated as:
Clearbridge Health's share price for today is €0.0005.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clearbridge Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Clearbridge Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5C6 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Clearbridge Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearbridge Health EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clearbridge Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clearbridge Health's EV-to-EBITDA falls into.
Clearbridge Health's current Enterprise Value is €6.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clearbridge Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-7.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearbridge Health (FRA:5C6) has a EV-to-EBITDA of -0.87 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clearbridge Health. According to the industry distribution chart, Clearbridge Health ranks #999999 out of 123 companies in the Medical Diagnostics & Research industry.
Is Clearbridge Health's EV-to-EBITDA too high?
Clearbridge Health's current EV-to-EBITDA is -0.87. Based on the distribution chart, Clearbridge Health ranks #999999 out of 123 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Clearbridge Health's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clearbridge Health ranks #999999 out of 123 companies for EV-to-EBITDA. This places Clearbridge Health in the lower half of its industry. The industry median EV-to-EBITDA is 16.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.06, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Clearbridge Health. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearbridge Health's current EV-to-EBITDA is -0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearbridge Health stock overvalued right now?
Clearbridge Health (FRA:5C6) has a current EV-to-EBITDA of -0.87. The current EV-to-EBITDA is -0.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Clearbridge Health (FRA:5C6), the current EV-to-EBITDA is -0.87 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearbridge Health Ltd provides health care services. It is an integrated healthcare group with end-to-end diagnostic abilities, deploying non-invasive tests to identify and manage illness. The segments are Strategic investments; Others ; Medical clinics; Corporate segment and Investment. It derives key revenue from the Medical clinics segment. The medical clinics/centres segment involves the provision of general medical, dental and clinical services and distribution of the medical and pharmaceutical products. The group has a business presence in Singapore, Philippines, Hong Kong, Malaysia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5C6 has been successfully added to your 
